FHM和FAM方案治疗进展期胃癌疗效观察

• 作 者: 赵君慧 李国元 林明哲
• 机 构: 青海医学院附属肿瘤医院内科,青海医学院附属肿瘤医院内科,青海医学院附属肿瘤医院内科 西宁 810001,西宁 810001,西宁 810001
• 出 处: 陕西医学杂志
• 发表日期: 1998年06期
• 关键词: FAM方案 FHM 治疗应用 胃肿瘤 氟脲嘧啶 喜树碱 心脏毒性 低分化腺癌 新辅助化疗 药物疗法

采用随机对照的方法,以FHM或FAM方案治疗进展期胃癌49例,每例均以静脉给药,21d为1疗程,治疗3疗程。疗效和毒性用卡方检验。结果提示,FHM和FAM两组有效率分别为41.6％(10/24)和44.0％(11/25),半年生存率分别为50％和56％,且毒性均可耐受。说明了FHM与FAM方案疗效相似,而FHM组无心脏毒性,并且二者能提高进展期胃癌的疗效和手术切除率。

A randomized controlled method was used to treat 49 cases of advanced gastric cancer with FHM or FAM regimens. Each case was administered intravenously, 21d was a course of treatment, and 3 courses of treatment were given. Efficacy and toxicity were tested using the chi-square test. The results suggest that the effective rates of FHM and FAM were 41.6% (10/24) and 44.0% (11/25) respectively, and the half-year survival rates were 50% and 56%, respectively, and the toxicity was tolerable. It was demonstrated that the efficacy of FHM was similar to that of the FAM regimen, whereas the FHM group had no cardiotoxicity and both improved the efficacy and surgical resection rate of advanced gastric cancer.